Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 16/20 | 0.47 |
| ▸ | JAK2 | O60674 | 12/20 | 0.47 |
| ▸ | JAK1 | P23458 | 8/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.47 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.47 |
| ▸ | TYK2 | P29597 | 4/20 | 0.47 |
| ▸ | RET | P07949 | 4/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.47 |
| ▸ | STK3 | Q13188 | 3/20 | 0.47 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.47 |
| ▸ | LCK | P06239 | 3/20 | 0.47 |
| ▸ | CAMK1D | Q8IU85 | 3/20 | 0.47 |
| ▸ | MARK3 | P27448 | 2/20 | 0.47 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.47 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | FYN | P06241 | 2/20 | 0.47 |
| ▸ | DMPK | Q09013 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12395298 | 0.82 | JAK3 (0.53) | JAK3JAK2JAK1ROCK1PKN2 | |
| SCHEMBL1847638 | 0.81 | HSD11B1 (0.50) | JAK2JAK1MEN1ALDH1A1MAPT | |
| SCHEMBL1848190 | 0.81 | HSD11B1 (0.50) | JAK2JAK1MEN1ALDH1A1MAPT | |
| SCHEMBL12463220 | 0.80 | JAK3 (0.54) | JAK3JAK2JAK1ROCK1PKN2 | |
| SCHEMBL9921655 | 0.80 | JAK3 (0.52) | JAK3JAK2JAK1ROCK1PKN2 | |
| SCHEMBL1992463 | 0.78 | JAK3 (0.46) | JAK3JAK2JAK1ROCK1PKN2 | |
| SCHEMBL2053385 | 0.78 | JAK3 (0.46) | JAK3JAK2JAK1ROCK1PKN2 | |
| SCHEMBL1992462 | 0.78 | JAK3 (0.46) | JAK3JAK2JAK1ROCK1PKN2 | |
| SCHEMBL1992467 | 0.78 | JAK3 (0.46) | JAK3JAK2JAK1ROCK1PKN2 | |
| SCHEMBL19275337 | 0.78 | JAK3 (0.50) | JAK3JAK2JAK1ROCK1PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2010014930-A2 | THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | JAK3 1/4885JAK2 2/4885JAK1 3/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | JAK3 3/4885JAK2 1/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.